

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

UBXN2B RABBIT PAB

货号: S218100

产品全名: UBXN2B 兔多抗

基因符号 p37

UNIPROT ID: Q14CS0 (Gene Accession - BC113645)

背景: UBXD2B (UBX domain-containing protein 2B), also known as NSFL1 cofactor p37 and p97 cofactor p37, is a 331 amino acid protein that contains one UBX domain and one SEP domain. UBXN2B is required for ER and Golgi biogenesis and also plays a role in their maintenance during interphase, as well as their reassembly at the end of mitosis. Through interaction with VCP, UBXN2B forms a complex that has membrane fusion activity. Adapter protein required for Golgi and endoplasmic reticulum biogenesis. Involved in Golgi and endoplasmic reticulum maintenance during interphase and in their reassembly at the end of mitosis. The complex formed with VCP has membrane fusion activity; membrane fusion activity requires USO1-GOLGA2 tethering and BETIL. VCPIPI is also required, but not its deubiquitinating activity.

抗原: Fusion protein of human UBXN2B

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 5000-10000

种属反应性: Rabbit


克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Signal Transduction

储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human esophagus cancer tissue using 218100(UBXN2B Antibody) at a dilution Human esophagus cancer tissue is first treated with the fusion of 1/20(Nucleus or Cytoplasm)

In comparision with the IHC on the left, the same paraffin-embedded protein and then with 218100(Anti-UBXN2B Antibody) at dilution 1/20



The image on the left is immunohistochemistry of paraffinembedded Human thyroid cancer tissue using 218100(Anti-UBXN2B



In comparision with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with fusion protein and



Product Description

Pioneering GTPase and Oncogene Product Development since 2010